SLC5A2 and atrial fibrillation: Sodium glucose cotransporter-2 inhibitors (SGLT2is) have also been shown to be associated with lower risk of incident AF compared to GLP-1RA therapies, though both were shown to reduce AF risk compared to placebo[110,111].